Alnylam Pharmaceuticals Initiates Phase I Clinical Study Of ALN-RSV01, An RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 7, 2005-- Alnylam Becomes a Clinical-Stage Company with the Industry's First Trial of an RNAi Therapeutic for Viral Infectious Disease. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase I study in Europe to evaluate the human safety and pharmacology of ALN-RSV01, an RNAi therapeutic, in healthy volunteers. Additionally, the company's investigational new drug (IND) application to conduct a separate Phase I trial in the U.S. has cleared the 30-day review period by the Food and Drug Administration (FDA), and the U.S. study is expected to begin by the end of the month.

Back to news